A combination of PPAR-γ agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes)

Medical Hypotheses

Volumn 73, Issue 4, 2009, Pages 614-618

  Sorice, Gian Pio ^a   Folli, Franco ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAVASTATIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANEURYSM; ANTIINFLAMMATORY ACTIVITY; AORTA ANEURYSM; AORTA RUPTURE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CONSERVATIVE TREATMENT; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; IMMUNOMODULATION; INSULIN RESISTANCE; MARFAN SYNDROME; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; AORTIC ANEURYSM; CONNECTIVE TISSUE DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, CARDIOVASCULAR; PPAR GAMMA; SYNDROME;

EID: 69249231982     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.04.058     Document Type: Article

References (79)

1. Judge D.P., and Dietz H.C. Marfan's syndrome. Lancet 366 9501 (2005) 1965-1976
2. Silverman D.I., Burton K.J., Gray J., et al. Life expectancy in the Marfan syndrome. Am J Cardiol 75 2 (1995) 157-160
3. Prisant L.M., and Mondy III J.S. Abdominal aortic aneurysm. J Clin Hypertens (Greenwich) 6 2 (2004) 85-89
4. Santilli J.D., and Santilli S.M. Diagnosis and treatment of abdominal aortic aneurysms. Am Fam Physician 56 4 (1997) 1081-1090
5. Barbour J.R., Spinale F.G., and Ikonomidis J.S. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res 139 2 (2007) 292-307 [Epub 2007 Feb 9]
6. Wilson W.R., Anderton M., Schwalbe E.C., et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113 3 (2006) 438-445
7. Alexander J.J. The pathobiology of aortic aneurysms. J Surg Res 117 1 (2004) 163-175 [Review]
8. Isselbacher E.M. Thoracic and abdominal aortic aneurysms. Circulation 111 6 (2005) 816-828
9. Kainulainen K., Pulkkinen L., Savolainen A., Kaitila I., and Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. New Engl J Med 323 14 (1990) 935-939
10. Bunton T.E., Biery N.J., Myers L., Gayraud B., Ramirez F., and Dietz H.C. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 88 1 (2001) 37-43
11. Neptune E.R., Frischmeyer P.A., Arking D.E., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33 3 (2003) 407-411
12. Kaartinen V., and Warburton D. Fibrillin controls TGF-beta activation. Nat Genet 33 3 (2003) 331-332
13. Jones J.A., Spinale F.G., and Ikonomidis J.S. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res 46 2 (2009) 119-137
14. Gelb B.D. Marfan's syndrome and related disorders-more tightly connected than we thought. New Engl J Med 355 8 (2006) 841-844
15. Pearce W.H., and Shively V.P. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann NY Acad Sci. 1085 (2006) 117-132
16. Loeys B.L., Schwarze U., Holm T., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. New Engl J Med 355 8 (2006) 788-798
17. Singh K.K., Rommel K., Mishra A., et al. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Human Mutat 27 8 (2006) 770-777
18. Pope F.M., Narcisi P., Nicholls A.C., Germaine D., Pals G., and Richards A.J. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. Br J Dermatol 135 2 (1996) 163-181
19. Loeys B.L., Chen J., Neptune E.R., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37 3 (2005) 275-281
20. Boutouyrie P., Germain D.P., Fiessinger J.N., Laloux B., Perdu J., and Laurent S. Increased carotid wall stress in vascular Ehlers-Danlos syndrome. Circulation 109 12 (2004) 1530-1535
21. Pannu H., Avidan N., Tran-Fadulu V., and Milewicz D.M. Genetic basis of thoracic aortic aneurysms and dissections: potential relevance to abdominal aortic aneurysms. Ann NY Acad Sci 1085 (2006) 242-255
22. Zhu L., Vranckx R., Khau Van Kien P., et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 38 3 (2006) 343-349
23. Guo D.C., Pannu H., Tran-Fadulu V., et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 39 12 (2007) 1488-1493
24. Pannu H., Tran-Fadulu V., and Milewicz D.M. Genetic basis of thoracic aortic aneurysms and aortic dissections. Am J Med Genet C Semin Med Genet 139C 1 (2005) 10-16
25. Boddy A.M., Lenk G.M., Lillvis J.H., Nischan J., Kyo Y., and Kuivaniemi H. Basic research studies to understand aneurysm disease. Drug News Perspect 21 3 (2008) 142-148
26. Shi Y., and Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 6 (2003) 685-700 [Review]
27. Jones J.A., Barbour J.R., Stroud R.E., et al. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res 45 6 (2008) 457-468
28. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 67 (1998) 753-791
29. Miyazono K., ten Dijke P., and Heldin C.H. TGF-beta signaling by Smad proteins. Adv Immunol 75 (2000) 115-157 [Review]
30. Massagué J., and Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19 8 (2000) 1745-1754 [Review]
31. Moustakas A., and Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 118 Pt 16 (2005) 3573-3584
32. Yu L., Hébert M.C., and Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 21 14 (2002) 3749-3759
33. Nataatmadja M., West J., and West M. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation 114 Suppl. 1 (2006) I371-1377
34. Law R.E., Goetze S., Xi X.P., et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101 11 (2000) 1311-1318
35. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 4 (1998) 507-514
36. Göke B. German pioglitazone study group. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 1 5 (2002) 329-336
37. Gurnell M., Savage D.B., Chatterjee V.K., and O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 88 6 (2003) 2412-2421
38. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 4 (2000) 527-550
39. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 9 (2004) 1168-1178 [Review]
40. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95 13 (1998) 7614-7619
41. Kwak B.R., Myit S., Mulhaupt F., et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells. Circ Res 90 3 (2002) 356-362
42. Kwak B.R., Mulhaupt F., and Mach F. The role of PPARgamma ligands as regulators of the immune response. Drug News Perspect 15 6 (2002) 325-332
43. Ishibashi M., Egashira K., Hiasa K., et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40 5 (2002) 687-693
44. Shiomi T., Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 24 (2002) 3126-3132
45. Soumian S., Gibbs R., Davies A., and Albrecht C. MRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease. J Clin Pathol 58 12 (2005) 1255-1260
46. Ghosh A.K., Bhattacharyya S., Lakos G., Chen S.J., Mori Y., and Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50 4 (2004) 1305-1318
47. Routh R.E., Johnson J.H., and McCarthy K.J. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 61 4 (2002) 1365-1376
48. Fornoni A., Striker L.J., Zheng F., and Striker G.E. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 51 2 (2002) 499-505
49. Galli A., Ceni E., Crabb D.W., et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 53 11 (2004) 1688-1697
50. Kon K., Ikejima K., Hirose M., et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291 1 (2002) 55-61
51. Masamune A., Kikuta K., Satoh M., Sakai Y., Satoh A., and Shimosegawa T. Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. J Biol Chem 277 1 (2002) 141-147
52. Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 46 (2000) 35715-35722
53. Dzan V.J., and Creager M.A. In: Braunwald E., Fauci A.S., Kasper D.L., Hauser S.L., Longo D.L., and Jameson J.L. (Eds). Diseases on the Aorta Harrison's principles of internal medicine. 15th ed. (2001), McGraw-Hill Professional Publishing, New York 1430-1434 [Chapter 247]
54. Williams A., Davies S., Stuart A.G., Wilson D.G., and Fraser A.G. Medical treatment of Marfan syndrome: a time for change. Heart 94 4 (2008) 414-421
55. Keane M.G., and Pyeritz R.E. Medical management of Marfan syndrome. Circulation 117 21 (2008) 2802-2813
56. da Cunha V., Tham D.M., Martin-McNulty B., et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178 1 (2005) 9-17
57. Canavesi M., Baldini N., Leonardi A., Sironi G., Bellosta S., and Bernini F. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol 44 4 (2004) 416-422
58. Morishita R., and Tomita N. Effect of nifedipine on organ protection: potential application in patients with aortic aneurysm. Drugs 66 Spec No. 1 (2006) 31-33 [Review]
59. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 5770 (2006) 117-121
60. Lavoie P., Robitaille G., Agharazii M., Ledbetter S., Lebel M., and Larivière R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 23 10 (2005) 1895-1903
61. Ejiri J., Inoue N., Tsukube T., et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 59 4 (2003) 988-996
62. Keating G.M., and Robinson D.M. Rosuvastatin: a review of its effect on atherosclerosis. Am J Cardiovasc Drugs 8 2 (2008) 127-146 [Review]
63. Kong D.F. Aspirin in cardiovascular disorders. What is the optimum dose?. Am J Cardiovasc Drug 4 3 (2004) 151-158 [Review]
64. Ince H., and Nienaber C.A. Etiology, pathogenesis and management of thoracic aortic aneurysm. Nat Clin Pract Cardiovasc Med 4 8 (2007) 418-427 [Review]
65. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 359 21 (2008) 2195-2207 [Epub 2008 Nov 9]
66. Gómez-Hernández A., Sánchez-Galán E., Martín-Ventura J.L., et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol 47 1 (2006) 60-69
67. Mehta J.L., Chen J., Yu F., and Li D.Y. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 64 2 (2004) 243-249
68. Hua Y., Xue J., Sun F., Zhu L., and Xie M. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPAR alpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 83 1 (2009) 18-25
69. Brooke B.S., Habashi J.P., Judge D.P., Patel N., Loeys B., and Dietz III H.C. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. New Engl J Med 358 26 (2008) 2787-2795
70. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 3 (2000) 704-711
71. Igarashi M., Takeda Y., Ishibashi N., et al. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm Metab Res 29 9 (1997) 444-449
72. Toba H., Miki S., Shimizu T., et al. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta. Eur J Pharmacol 549 1-3 (2006) 124-132 [Epub 2006 Aug 30]
73. Joner M., Farb A., Cheng Q., et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27 1 (2007) 182-189 [Epub 2006 Oct 26]
74. Imanishi T., Kobayashi K., Kuroi A., Ikejima H., and Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res 31 4 (2008) 757-765
75. Chen J., and Mehta J.L. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291 4 (2006) H1738-H1745
76. Folli F., Kahn C.R., Hansen H., Bouchie J.L., and Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100 9 (1997) 2158-2169
77. Velloso L.A., Folli F., Sun X.J., White M.F., Saad M.J., and Kahn C.R. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93 22 (1996) 12490-12495
78. Muscogiuri G., Chavez A.O., Gastaldelli A., et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 6 4 (2008) 301-312
79. Pande R.L., and Beckman J.A. Abdominal aortic aneurysm: populations at risk and how to screen. J Vasc Interv Radiol 19 6 Suppl. (2008) S2-S8 Review